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Pulmonary Alveolar Proteinosis (PAP) is a rare condition with an incidence of one in two million and
is classiﬁed as primary or secondary. This is the ﬁrst reported case presenting as a slow resolving
pneumonia.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
A 79-year-old lady of Nigerian origin living in the UK presented
with a right basal pneumonia. She was in remission from chronic
lymphocytic leukaemia, diagnosed in 1999.
She had a slow to resolve right basal consolidation (Fig. 1),
despite multiple courses of antibiotics. Her CT scan showed a large
area of irregular consolidation in the middle lobe, extending into
the upper lobe (Fig. 2).
The patient was further investigated with a bronchoscopy,
showing no endobronchial lesion. A blind endobronchial biopsy
and bronchoalveolar lavage did not show any features to support
the diagnosis of malignancy or atypical infection. She underwent a
CT guided biopsy of the middle lobe consolidation. This excluded
malignancy, however showed features of Pulmonary Alveolar
Proteinosis (PAP) (Fig. 3).2. Discussion
Rosen et al. ﬁrst described Pulmonary Alveolar Proteinosis, a
rare diffuse lung disease [1,2], in 1958 [3]. There is a large intra-hs.uk (A. Kavidasan).
-NC-ND license.alveolar accumulation of surfactant [4] with lipoproteinaceous
material [2,3,5,6], disrupting the transfer of oxygen [1,7].
The epidemiology suggests PAP is as rare as one case in every
two million [5] and more common in males by 3:1 [8]. The onset is
in the third or fourth decade.
PAP can be primary or secondary, however most cases are pri-
mary [5]. The classiﬁcation includes two congenital forms and there
are suggestions that PAP may be part of a syndrome [5,9].
This presentation of a patient with an unresolving pneumonia
and diagnosis of PAP is probably the ﬁrst in the literature. The
diagnosis is most likely related to the patient’s chronic lymphocytic
leukaemia (CLL) and thus is secondary PAP.
The incidence of PAP in a person with a haematological malig-
nancy (usually myeloid) is 5.3% [5] and therefore the case of PAP in
this patient is likely to be even less common as the leukaemia is
leucocytic.
Patients with PAP usually present with dyspnoea [1,5] and a
cough [1,2]. Approximately 75% of patients are smokers at diagnosis
[1,2,8]. Blood tests can highlight a high lactate dehydrogenase
(LDH) and raised tumour markers. Spirometry shows a restrictive
pattern [1,2,8], although can be obstructive in smokers. Blood gases
can predict the clinical course, for instance a PaO2 of over 9.3 kPa
can mean a patient is more likely to recover [5].
Imaging shows non-speciﬁc bilateral patchy consolidation
[1,2,5] and approximately 20% have unilateral abnormalities.
Fig. 1. Chest X-ray illustrating right basal consolidation.
Fig. 3. Lung Biopsy (Periodic acid Schiff stain): Alveolar spaces are ﬁlled by homoge-
nous faintly eosinophilic material, staining positive on PAS stain and resistant to dia-
stase digestion. The lung interstitium shows lymphatic dilation and a small collection
of lymphocytes. The features are those of alveolar proteinosis.
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specimens. A tissue biopsymay not always yield the diagnosis if the
consolidation is patchy.
The gold standard for treatment of primary PAP is whole lung
lavage [1,4,5]. There have been various treatments used in the past,
such as steroids, streptokinase and potassium iodide [5]. There is a
report of one patient improving in response to ambroxol, despite
this causing an increased production of surfactant [5]. One alter-
native treatment is aerolsolised trypsin, although this can lead to
allergic reactions and proteolytic damage [5,7]. Another is
granulocyte-macrophage colony-stimulating factor (GM-CSF),
which can clear surfactant and be used in patients resistant to lung
lavage [1,4]. However, this can be expensive and the patient may go
into cardiac failure. Three trials have also shown that patients can
relapse after this treatment, although there is a beneﬁt in some
patients [10e13]. Gene therapymay be a potential future treatment
in congenital PAP.Fig. 2. CT scan showing a large area of irregular consolidation in the middle lobe
extending into the upper lobe.PAP is classiﬁed as secondary if related to a medical condition
such as a malignancy [2] (particularly myeloid leukaemia)
[1,3,6,8,14], pulmonary infection, immunodeﬁciency or as a result
of the inhalation of chemicals [1,2,8,14]. Secondary PAP accounts for
5e10% of all cases [1,2]. One study shows a patient with secondary
PAP receiving GM-CSF had no change in their condition, one
improved with stem cell transplantation and the other with anti-
fungal treatment [6]. Another did well with no treatment inter-
vention [6].
The pathophysiology of secondary PAP in those with a haema-
tological malignancy is that alveolar macrophages are abnormal
[6,8,14] as they originate from the malignant clone and have mal-
functioning GM-CSF transduction [6,15]. This therefore leads to a
build up of surfactant [16]. The mainstay of treatment is managing
the underlying malignancy [1,6,9]. Whole lung lavage and GM-CSF
therapy are options.
In conclusion, the literature mainly discusses treatments for
primary and congenital PAP. As secondary PAP is extremely rare,
there is no speciﬁc recommended therapy. Treatment is centred on
treating the underlying cause [1,5,6] and providing symptomatic
relief.
The prognosis of PAP can be worse with atypical infections such
as pneumocystis carinii [2], mycobacterium and viruses [1,5,8]. This
leads to increased morbidity [1] and mortality for patients with
secondary PAP [6]. The accumulation of surfactant encourages
microorganisms to grow and the susceptibility is further increased
by abnormal macrophages [6,7]. The use of steroids should there-
fore not be encouraged [5]. Ultimately, the prognosis of secondary
PAP is dependent on the course of the underlying disease.
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